Using Biolimus-Coated Balloons for Treating Small-Vessel Disease Yields Promising Results

Drug-eluting balloons have demonstrated safety and effectiveness in the treatment of small-vessel coronary artery disease and in-stent restenosis. However, randomized studies were performed using paclitaxel.

Resultados alentadores de los balones cubiertos de Biolimus para el tratamiento de vasos pequeños

Several studies have shown that using biolimus, a semisynthetic analog of sirolimus, optimizes drug delivery in both stents and balloons.

The aim of this randomized, multicenter study was to evaluate the safety and effectiveness of the biolimus-coated balloon (BCB) in patients with small-vessel coronary artery disease (reference vessel diameter 2.0 to 2.75 mm and length ≤25 mm) undergoing coronary angioplasty.

The primary endpoint (PEP) was vessel lumen narrowing at 9 months as measured by angiography. The secondary endpoint (SEP) included restenosis, and procedural, lesion, and device success.

Clinical outcomes were evaluated up to a 1-year follow-up and included cardiovascular death, treated-vessel-related acute myocardial infarction, clinically guided revascularization, and treated-vessel failure, among others.

A total of 212 patients were included and randomized as follows: 106 to the BCB group and 103 to the balloon angioplasty group; the remaining 3 were excluded because they did not receive the device.

Read also: Should We Start Thinking Again About Bioresorbable Stents?

Mean patient age was 61 years old, and 30% of subjects were female. The most frequent clinical presentation was unstable angina. The number of lesions treated in >95% of patients was 1. Pre-dilation was achieved in all cases and the number of pre-dilations in most patients was 1.

For the PEP, BCB was superior to balloon angioplasty (p = 0.001). The restenosis rate was lower in the BCB group, with 9.9% vs. 28% in the balloon group (p = 0.001). There were no differences in the SEP nor in clinical events at 1 year.

Conclusion

This randomized study has demonstrated the safety and efficacy of the new biolimus-coated balloon in patients with small-vessel coronary artery disease. Positive vascular remodeling was 3 times more frequent when using these devices, and there was a non-significant trend in clinical improvement at 1 year.

Dr. Andrés Rodríguez
Member of the Editorial Board of SOLACI.org.

Original Title: Biolimus-Coated Balloon in Small-Vessel Coronary Artery Disease The BIO-RISE CHINA Study.

Reference: Kai Xu, MD et al J Am Coll Cardiol Intv 2022.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....